Bevacizumab gamma
As of the edition of 20 October 2026, Bevacizumab gamma is an antibody: marketed, first approved in 2026 (US); acts on VEGFA; US protection ends in 2038.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Antibody
- Brand name
- Lytenava
- First approved
- 24 July 2026 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Outlook Therapeutics
US protection
US protection ends in 2038.
US protection ends in 2038, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Outlook Therapeutics. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| VEGFA | Vascular endothelial growth factor A, long form | P15692 |